AGP Executive Report
Last update: a day agoHeat & Safety: Europe’s deadly spring heat wave has shattered temperature records, with at least 18 deaths reported in the U.K. and more feared as extreme heat persists. Cancer Care (Liechtenstein included): AbbVie says the European Commission authorized expanded use of VENCLYXTO (venetoclax) for previously untreated chronic lymphocytic leukemia, including new fixed-duration combinations that may offer treatment-free intervals. Bladder Cancer (Europe-wide): The EU CHMP issued a positive opinion for perioperative pembrolizumab plus enfortumab vedotin for certain cisplatin-ineligible muscle-invasive bladder cancer patients, with a final EC decision expected in Q3 2026. Transplant Outcomes: Hansa Biopharma reports strong one-year results for Idefrix (imlifidase) in highly sensitised kidney transplant patients, including 90% graft failure-free survival. Immunodeficiency Treatment: Pharming received EU marketing authorization for Joenja (leniolisib) for activated PI3K delta syndrome, with availability planned across EU countries including Liechtenstein. Travel Health/Rules: UK authorities warn travellers not to bring meat or dairy from the EU, with fines up to £5,000 and possible prosecution for undeclared items.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
